References
- Beckett AH. 1971. Metabolic oxidation of aliphatic basic nitrogen atoms and their alpha-carbon atoms. Xenobiotica. 1(4):365–383. doi: 10.3109/00498257109041503.
- Caldwell RD, Qiu H, Askew BC, Bender AT, Brugger N, Camps M, Dhanabal M, Dutt V, Eichhorn T, Gardberg AS, et al. 2019. Discovery of Evobrutinib: an oral, potent, and highly selective covalent Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of immunological diseases. J Med Chem. 62(17):7643–7655. doi: 10.1021/acs.jmedchem.9b00794.
- Food and Drug Administration. 2020. Safety testing of drug metabolites: guidance for industry. Maryland (USA): US Department of Health and Human Services. Center for Drug Evaluation and Research (CDER); p. 11.
- Green DE, Forrest IS. 1966. In vivo metabolism of chlorpromazine. Can Psychiatr Assoc J. 11(4):299–302. doi: 10.1177/070674376601100405.
- Gross G, Wilson I. 2009. Issues in the safety testing of metabolites. Future Med Chem. 1(8):1381–1390. doi: 10.4155/fmc.09.101.
- Huang CL. 1967. Isolation and identification of urinary chlorpromazine metabolites in man. Int J Neuropharmacol. 6(1):1–13. doi: 10.1016/0028-3908(67)90037-8.
- Nicholson JK, Wilson ID. 2003. Understanding ‘global’ systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov. 2(8):668–676. doi: 10.1038/nrd1157.
- Schadt S, Bister B, Chowdhury SK, Funk C, Hop CECA, Humphreys WG, Igarashi F, James AD, Kagan M, Khojasteh SC, et al. 2018. A decade in the MIST: learnings from investigations of drug metabolites in drug development under the “Metabolites in Safety Testing” regulatory guidance. Drug Metab Dispos. 46(6):865–878. doi: 10.1124/dmd.117.079848.
- Scheible H, Dyroff M, Seithel-Keuth A, Harrison-Moench E, Mammasse N, Port A, Bachmann A, Dong J, van Lier JJ, Tracewell W, et al. 2021. Evobrutinib, a covalent Bruton’s tyrosine kinase inhibitor: mass balance, elimination route, and metabolism in healthy participants. Clin Transl Sci. 14(6):2420–2430. doi: 10.1111/cts.13108.
- Scheible H, Schieferstein H, Schmidt R, Pusecker K, Gradhand U, Gopalakrishnan S, Iqbal K, Dong J, Jones R, Meli C, et al. 2023. Evobrutinib pathway to its major metabolite M463-2 and insights from a biotransformation and DDI perspective. Xenobiotica. 53(8-9):547–558. doi: 10.1080/00498254.2023.2272180.
- Verpoorte R, Kim HK, Choi YH. 2022. Trivialities in metabolomics: artifacts in extraction and analysis. Front Mol Biosci. 9:972190. doi: 10.3389/fmolb.2022.972190.
- Wang S, Ballard TE, Christopher LJ, Foti RS, Gu C, Khojasteh SC, Liu J, Ma S, Ma B, Obach RS, et al. 2023. The importance of tracking “missing” metabolites: how and why? J Med Chem. 66(23):15586–15612. doi: 10.1021/acs.jmedchem.3c01293.
- Williams RT. 1959. Detoxication mechanisms - the metabolism and detoxication of drugs, toxic substances and other organic compounds. 2nd edn. London: Chapman & Hall. p. 667.